Novo Nordisk and Signet collaborate to deliver quats to India

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/AvigatorPhotographer)
(Image: Getty/AvigatorPhotographer)

Related tags Novo Nordisk Pharmatech Signet Quats India

Novo Nordisk announced a distribution agreement that will see quats delivered by Signet to the healthcare industry in India, as well as Bangladesh and Sri Lanka.

As part of its role in the agreement, Novo Nordisk Pharmatech will manufacture various quaternary ammonium compounds (quats) for Signet Chemical Corporation.

Signet, an India-based company focused on the excipient market, will then deliver the products to its markets in South Asia.

Harish Shah, managing director of Signet, commented on the collaboration: “We are pleased to be associated with Novo Nordisk Pharmatech which is the leading supplier of quats to the pharmaceutical and biopharmaceutical markets. Novo Nordisk Pharmatech’s FeF quats complement our existing portfolio of excipients used especially for ophthalmic, nasal and topical dosage forms.”

Novo Nordisk currently produces Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide quats, with the active pharmaceutical ingredients (APIs) manufactured at its site based in Koege, Denmark.

“We are very happy to work with Signet as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF quats products fit perfectly with Signet’s wide range of excipients enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma team of Signet are experts in working with customers to support their product development,” ​said Steve Profit, sales and marketing director at Novo Nordisk Pharmatech.

At the time of publishing, Signet had not responded to a request for comment.

Related news

Related product

A Guide Through the API Drug Development Pipeline.

A Guide Through the API Drug Development Pipeline.

Content provided by Lonza Small Molecules | 04-Apr-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more